Interpace Biosciences Inc PEG
Was ist das PEG von Interpace Biosciences Inc?
PEG von Interpace Biosciences Inc ist N/A
Was ist die Definition von PEG?
Das Kurs-Gewinn-Wachstums-Verhältnis (PEG) ist das KGV einer Aktie geteilt durch eine erwartete Wachstumsrate des Gewinns über einen Zeitraum von 5 Jahren.
The PEG ratio is calculated by dividing the P/E ratio by the company's expected earnings growth rate in the next 5 years. Since using just the P/E ratio would make high-growth companies appear overvalued relative to others, the PEG ratio is considered to be a convenient approximation. PEG is a widely employed indicator of a stock's possible true value.
Similar to P/E ratios, a lower PEG means that the stock is undervalued more. It is favored by many over the price/earnings ratio because it also accounts for growth. The PEG ratio of 1 is sometimes said to represent a fair trade-off between the values of cost and the values of growth, indicating that a stock is reasonably valued given the expected growth. A crude analysis suggests that companies with PEG values between 0 and 1 may provide higher returns. A PEG Ratio can also be a negative number if a stock's present income figure is negative, (negative earnings) or if future earnings are expected to drop (negative growth). PEG ratios calculated from negative present earnings are viewed with skepticism as almost meaningless, other than as an indication of high investment risk.
PEG von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Interpace Biosciences Inc
Was macht Interpace Biosciences Inc?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Unternehmen mit peg ähnlich Interpace Biosciences Inc
- Otonomy Inc hat PEG von N/A
- Akcea Therapeutics Inc hat PEG von N/A
- Bombardier hat PEG von N/A
- Dawson Geophysical hat PEG von N/A
- Entercom Communications Corp hat PEG von N/A
- Town Sports International hat PEG von N/A
- Interpace Biosciences Inc hat PEG von N/A
- Aqua Metals Inc hat PEG von N/A
- Babcock & Wilcox Enterprises Inc hat PEG von N/A
- Ferroglobe Plc hat PEG von N/A
- Icon hat PEG von N/A
- Sorrento Therapeutics Inc hat PEG von N/A
- United States Steel hat PEG von N/A